STOCK TITAN

Gamida Cell Ltd - GMDA STOCK NEWS

Welcome to our dedicated news page for Gamida Cell (Ticker: GMDA), a resource for investors and traders seeking the latest updates and insights on Gamida Cell.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gamida Cell's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gamida Cell's position in the market.

Rhea-AI Summary
Gamida Cell Ltd. will release its financial results for Q3 2023 on November 14, 2023. The company will also provide business updates and host a conference call and live webcast to discuss the financial results and answer questions. Conference call details: Date/Time: November 14, 2023 at 8:30 AM Eastern Time. Domestic dial-in: 1-877-425-9470. International dial-in: 1-201-389-0878. Conference ID: 13741024. Webcast replay will be available on the company's website for approximately 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
conferences earnings
-
Rhea-AI Summary
Gamida Cell announces promising early data in Phase 1 study of GDA-201 for B cell non-Hodgkin lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Gamida Cell provides update on operations in Israel following recent attacks
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Abbey Jenkins, President and CEO of Gamida Cell, will present corporate highlights and commercial launch updates for Omisirge at the annual Cell & Gene Meeting on the Mesa. The event will feature over 100 presentations on cell and gene therapies. Virtual attendance is available. Omisirge is a cell therapy indicated for use in adults and pediatric patients with hematologic malignancies. Important safety information and contraindications are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences
-
Rhea-AI Summary
Gamida Cell (GMDA) to present at SITC 2023, showcasing GDA-201 and omidubicel graft research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
conferences
-
Rhea-AI Summary
Gamida Cell announces the first patient receiving a stem cell transplant with Omisirge, their allogeneic stem cell therapy. The company has exceeded its 2023 launch goals, with 15 transplant centers onboarded and coverage with payers that cover 90% of commercial lives. Gamida Cell market analyses indicate that Omisirge has the ability to capture approximately 20% of allogeneic stem cell transplant market share by ~2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
none
Rhea-AI Summary
Gamida Cell (GMDA) to present corporate highlights at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
conferences
-
Rhea-AI Summary
Gamida Cell reports strong start for Omisirge launch, exceeding expectations with payer coverage and transplant centers onboarded. Cash runway extended to Q2 2024 with $9 million reduction in debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
-
Rhea-AI Summary
Gamida Cell Ltd. will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. A conference call and live webcast will be held at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions. The webcast can be accessed on the Gamida Cell website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
conferences earnings
Rhea-AI Summary
Gamida Cell has published a sub-study of the Phase 3 clinical trial for Omisirge, its allogeneic stem cell transplant therapy. The study found that Omisirge facilitates faster immune reconstitution compared to umbilical cord blood (UCB), leading to a reduced rate of viral infections. Omisirge recipients demonstrated up to a 70-fold advantage in median cell counts across most cell populations, and received a 33-fold higher median dose of CD34+ stem cells than UCB recipients. The rate of grade 2/3 infections in the first year was significantly lower with Omisirge than with UCB.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
Gamida Cell Ltd

Nasdaq:GMDA

GMDA Rankings

GMDA Stock Data

4.34M
120.38M
11.58%
26.49%
7.53%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Jerusalem

About GMDA

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.